Tempus AI Acquires Pharmacogenomics Assets of Bankrupt IVD Firm OneOme

Tempus confirmed to GenomeWeb on Monday this week that it has acquired the PGx assets of this struggling Minneapolis company. OneOme is a spin-off from the Mayo Clinic.Tempus said it could not provide further comment on the deep strategy of this acquisition and did not disclose the financial details of the deal.

OneOme, which operates a CLIA-certified laboratory and offers the 27-gene RightMed PGx test, ceased operations on November 7.The company, co-founded a decade ago by Mayo Clinic and venture catalyst Invenshure, once gained prominence in the PGx field. However, according to sources, OneOme has been facing financial difficulties for nearly a year or longer and has been seeking a buyer.

Chicago-based Tempus, primarily known as a cancer molecular diagnostics company, offers a range of next-generation sequencing DNA and RNA tests for tissue and liquid biopsies, as well as minimal residual disease testing for cancer monitoring. Therefore, it may be the ideal destination for OneOme's PGx assets. Tempus already provides PGx testing services, but OneOme’s established partnerships with numerous healthcare systems will enable Tempus to further expand in this market.

Despite financial difficulties, OneOme had previously obtained approval from the New York State Department of Health for its RightMed test and established partnerships with dozens of healthcare systems across the United States. It even signed agreements to provide PGx testing in regions outside the U.S., such as Canada, Mexico, and Australia. The company's sudden closure has forced its PGx testing clients to scramble for alternatives.

"To some extent, the fit of this acquisition lies in OneOme's existing business connections and customer relationship network, rather than its technology itself," said Howard McLeod, a world-renowned PGx expert and Senior Vice President of Clinical Affairs at GeneDx. He added that clinicians seem to appreciate the way OneOme delivers PGx test reports and noted, "Tempus might be able to draw some inspiration from this approach."

This year, Tempus has been aggressively expanding its testing portfolio and services through mergers and acquisitions. In February 2025, Tempus acquired Ambry Genetics from Konica Minolta to enhance its in-house hereditary cancer screening capabilities and expand into genetic testing for pediatrics, rare diseases, immunology, women's reproductive health, and cardiology. In March, Tempus acquired Deep 6 AI, an AI-based software company specializing in extracting structured and unstructured patient data from electronic health records and matching patients to clinical trials. Then, in August, Tempus acquired Paige to broaden its reach in the digital pathology space.

Macleod pointed out that in the field of cancer care, guidelines regarding PGx testing are evolving, and oncologists increasingly need to consider testing for drug genes such as DPYD to manage treatment toxicity in patients. In light of this, he believes that now seems to be a good time for Tempus to strengthen its PGx capabilities, as its cancer testing services are already widely used by oncologists, and the company is also committed to expanding its influence in other disease areas.